This is a multi-centre, investigator-initiated, dose escalation, Phase I trial of the
combination of the FAK inhibitor, VS-6063, and the dual RAF/MEK inhibitor, RO5126766 in
patients with advanced solid tumours. RO5126766 is the same compound to CH5126766.
There are two parts to this study, the dose escalation phase and the dose expansion phase. In
the dose escalation phase, cohorts of 3 to 6 patients will be enrolled to determine the
maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). This will be followed by a
dose expansion phase to further characterise the safety and tolerability and to assess the
pharmacodynamic activity of the combination.